Min-Hee Ryu

Trials

Studies that name Min-Hee Ryu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:35 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT06732856 · A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer

  Asan Medical Center · recruiting · Stomach Neoplasm, Gastric (Stomach) Cancer · principal investigator
• Ph1
  NCT05978492 · A Study of TXN10128 in Subjects With Solid Tumors

  Txinno Bioscience Inc. · recruiting · Locally Advanced (Unresectable) or Metastatic Solid Tumors · principal investigator
• Ph2
  NCT04309578 · A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

  Asan Medical Center · completed · Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma · principal investigator
• Ph2
  NCT04221555 · Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

  Asan Medical Center · completed · Resectable Gastric or Gastroesophageal Junction Adenocarcinoma · principal investigator
• Ph2
  NCT03944304 · Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.

  Asan Medical Center · completed · Gastrointestinal Stromal Tumors · principal investigator
• Ph1/Ph2
  NCT03789617 · A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

  Eutilex · unknown · EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma · principal investigator
• Ph1/Ph2
  NCT03707028 · A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

  Elevar Therapeutics · terminated · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma · principal investigator
• Ph2
  NCT02712112 · A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs

  Asan Medical Center · completed · Gastrointestinal Stromal Tumors (GISTs) · principal investigator
• Ph3
  NCT01935778 · Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

  Asan Medical Center · recruiting · Gastric Cancer, Adjuvant Chemotherapy, XO · principal investigator
• Ph3
  NCT01917552 · Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

  Asan Medical Center · unknown · Gastric Cancer · principal investigator
• Ph3
  NCT01671449 · S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer

  Min-Hee Ryu · completed · Gastric Cancer · principal investigator
• Ph2
  NCT01541709 · Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

  Asan Medical Center · unknown · Gastrointestinal Stromal Tumors · principal investigator
• Ph1/Ph2
  NCT01525771 · Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer

  Asan Medical Center · completed · Stage IV Gastric Cancer With Metastasis · principal investigator
• N/A
  NCT01047618 · Venous Thromboembolism in Advanced Gastric Cancer Patients

  Asan Medical Center · completed · Advanced Gastric Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 03:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.